256 related articles for article (PubMed ID: 22547053)
1. The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients.
Stauder R
Ann Hematol; 2012 Sep; 91(9):1333-43. PubMed ID: 22547053
[TBL] [Abstract][Full Text] [Related]
2. Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management.
Burgstaller S; Wiesinger P; Stauder R
Drugs Aging; 2015 Nov; 32(11):891-905. PubMed ID: 26476843
[TBL] [Abstract][Full Text] [Related]
3. Personalized treatment strategies for elderly patients with myelodysplastic syndromes.
Castelli R; Bergamaschini L; Schiavon R; Lambertenghi-Deliliers G
Expert Rev Hematol; 2017 Dec; 10(12):1077-1086. PubMed ID: 29069953
[TBL] [Abstract][Full Text] [Related]
4. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.
Zeidan AM; Sekeres MA; Garcia-Manero G; Steensma DP; Zell K; Barnard J; Ali NA; Zimmerman C; Roboz G; DeZern A; Nazha A; Jabbour E; Kantarjian H; Gore SD; Maciejewski JP; List A; Komrokji R;
Leukemia; 2016 Mar; 30(3):649-57. PubMed ID: 26464171
[TBL] [Abstract][Full Text] [Related]
5. The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes.
Castelli R; Schiavon R; Deliliers GL
Med Oncol; 2018 Feb; 35(3):33. PubMed ID: 29417235
[TBL] [Abstract][Full Text] [Related]
6. Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes.
Papadopoulos V; Diamantopoulos PT; Papageorgiou SG; Papoutselis M; Vrachiolias G; Pappa V; Galanopoulos AG; Vassilakopoulos TP; Hatzimichael E; Zikos P; Papadaki HA; Bouchla A; Panayiotidis P; Megalakaki A; Papaioannou M; Liapis K; Dryllis G; Tsokanas D; Kourakli A; Symeonidis A; Viniou NA; Kotsianidis I
Hematol Oncol; 2020 Oct; 38(4):541-553. PubMed ID: 32495951
[TBL] [Abstract][Full Text] [Related]
7. Impact of age and comorbidity in myelodysplastic syndromes.
Stauder R; Nösslinger T; Pfeilstöcker M; Sperr WR; Wimazal F; Krieger O; Valent P
J Natl Compr Canc Netw; 2008 Oct; 6(9):927-34. PubMed ID: 18926101
[TBL] [Abstract][Full Text] [Related]
8. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.
Götze K; Platzbecker U; Giagounidis A; Haase D; Lübbert M; Aul C; Ganser A; Germing U; Hofmann WK
Ann Hematol; 2010 Sep; 89(9):841-50. PubMed ID: 20567826
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome.
Ritchie EK
Clin Interv Aging; 2012; 7():165-73. PubMed ID: 22791989
[TBL] [Abstract][Full Text] [Related]
10. Managing myelodysplastic symptoms in elderly patients.
Ria R; Moschetta M; Reale A; Mangialardi G; Castrovilli A; Vacca A; Dammacco F
Clin Interv Aging; 2009; 4():413-23. PubMed ID: 19966910
[TBL] [Abstract][Full Text] [Related]
11. Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.
Lee YJ; Park SW; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Lee WS; Lee SM; Joo YD; Kim H; Lee HS; Kim YS; Cho YY; Moon JH; Sohn SK
Ann Hematol; 2016 Oct; 95(11):1795-804. PubMed ID: 27530461
[TBL] [Abstract][Full Text] [Related]
12. Novel therapeutic strategies: hypomethylating agents and beyond.
Santini V
Hematology Am Soc Hematol Educ Program; 2012; 2012():65-73. PubMed ID: 23233562
[TBL] [Abstract][Full Text] [Related]
13. The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany.
Gattermann N; Kündgen A; Kellermann L; Zeffel M; Paessens B; Germing U
Eur J Haematol; 2013 Dec; 91(6):473-82. PubMed ID: 24102637
[TBL] [Abstract][Full Text] [Related]
14. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
Beran M
Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
[TBL] [Abstract][Full Text] [Related]
15. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
16. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
Aul C; Giagounidis A; Germing U; Ganser A
Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
[TBL] [Abstract][Full Text] [Related]
17. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Joeckel TE; Lübbert M
Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
[TBL] [Abstract][Full Text] [Related]
18. Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA registry.
Grinblatt DL; Sekeres MA; Komrokji RS; Swern AS; Sullivan KA; Narang M
Leuk Lymphoma; 2015 Apr; 56(4):887-95. PubMed ID: 24956145
[TBL] [Abstract][Full Text] [Related]
19. A novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndrome.
Asano M; Ohyashiki JH; Kobayashi-Kawana C; Umezu T; Imanishi S; Azuma K; Akahane D; Fujimoto H; Ito Y; Ohyashiki K
Drug Des Devel Ther; 2019; 13():1821-1833. PubMed ID: 31239639
[No Abstract] [Full Text] [Related]
20. Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes.
Balleari E; Salvetti C; Del Corso L; Filiberti R; Bacigalupo A; Bellodi A; Beltrami G; Bergamaschi M; Berisso G; Calzamiglia T; Carella AM; Cavalleri M; Da Col A; Favorini S; Forni GL; Goretti R; Miglino M; Mitscheuning L; Molinari E; Racchi O; Scudeletti M; Tassara R; Gobbi M; Lemoli R; Clavio M
Leuk Res; 2015 Aug; 39(8):846-52. PubMed ID: 26145790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]